Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.

Drumm MR, Dixit KS, Grimm S, Kumthekar P, Lukas RV, Raizer JJ, Stupp R, Chheda MG, Kam KL, McCord M, Sachdev S, Kruser T, Steffens A, Javier R, McCortney K, Horbinski C.

Neuro Oncol. 2019 Nov 10. pii: noz216. doi: 10.1093/neuonc/noz216. [Epub ahead of print]

PMID:
31711239
2.

Species Richness and Community Composition of Ants and Beetles in Bt and non-Bt Maize Fields.

Fernandes MG, Costa EN, Dutra CC, Raizer J.

Environ Entomol. 2019 Sep 30;48(5):1095-1103. doi: 10.1093/ee/nvz086.

PMID:
31287500
3.

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0449-8.

PMID:
30996326
4.

Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, Van den Bent M, Vogelbaum MA.

Neuro Oncol. 2019 Mar 18;21(4):424-427. doi: 10.1093/neuonc/noz034.

PMID:
30883663
5.

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NTN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, van den Bent M, Vogelbaum MA.

J Clin Oncol. 2019 May 1;37(13):1130-1135. doi: 10.1200/JCO.18.02085. Epub 2019 Mar 18.

PMID:
30883246
6.

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11. Erratum in: Nat Med. 2019 Apr 17;:.

7.

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.

Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, Glantz M, Groves MD, Lee EQ, Lin N, Raizer J, Rudà R, Weller M, Van den Bent MJ, Vogelbaum MA, Chang S, Wen PY, Soffietti R.

Neuro Oncol. 2019 May 6;21(5):571-584. doi: 10.1093/neuonc/noz012.

8.

Changes in social behavior are induced by pesticide ingestion in a Neotropical stingless bee.

Boff S, Friedel A, Mussury RM, Lenis PR, Raizer J.

Ecotoxicol Environ Saf. 2018 Nov 30;164:548-553. doi: 10.1016/j.ecoenv.2018.08.061. Epub 2018 Aug 24.

PMID:
30149353
9.

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.

Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jan 1;21(1):26-36. doi: 10.1093/neuonc/noy137.

PMID:
30137421
10.

Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression.

Huang RY, Unadkat P, Bi WL, George E, Preusser M, McCracken JD, Keen JR, Read WL, Olson JJ, Seystahl K, Le Rhun E, Roelcke U, Koeppen S, Furtner J, Weller M, Raizer JJ, Schiff D, Wen PY.

Neuro Oncol. 2019 Feb 14;21(2):234-241. doi: 10.1093/neuonc/noy126.

PMID:
30085283
11.

Widespread disseminated osseous metastases of intracranial meningioma with over 27-year-survivorship: a unique, idiosyncratic case.

Mishkin B, Raizer JJ, Bell JB.

J Neurooncol. 2018 Sep;139(3):781-783. doi: 10.1007/s11060-018-2926-1. Epub 2018 Jun 15. No abstract available.

PMID:
29948769
12.

Recent advances in managing/understanding meningioma.

Shaikh N, Dixit K, Raizer J.

F1000Res. 2018 Apr 24;7. pii: F1000 Faculty Rev-490. doi: 10.12688/f1000research.13674.1. eCollection 2018. Review.

13.

Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.

Robertson J, Raizer J, Hodges JS, Gradishar W, Allen JA.

J Peripher Nerv Syst. 2018 Jun;23(2):129-133. doi: 10.1111/jns.12271. Epub 2018 May 11.

PMID:
29696771
14.

Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.

Lukas RV, Gondi V, Stupp R, Raizer JJ.

Oncology (Williston Park). 2018 Feb 15;32(2):e11-e19. Review.

15.

Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis.

Lukas RV, Stupp R, Gondi V, Raizer JJ.

Oncology (Williston Park). 2018 Jan 15;32(1):17-22. Review.

16.

Newer Strategies for the Management of Low-Grade Gliomas.

Dixit K, Raizer J.

Oncology (Williston Park). 2017 Sep 15;31(9):680-2, 684-5.

17.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC.

Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.

18.

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.

Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP.

Transl Oncol. 2017 Aug;10(4):669-678. doi: 10.1016/j.tranon.2017.06.003. Epub 2017 Jun 30.

19.

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.

Kumthekar P, Grimm S, Chandler J, Mehta M, Marymont M, Levy R, Muro K, Helenowski I, McCarthy K, Fountas L, Raizer J.

J Neurooncol. 2017 Jul;133(3):589-594. doi: 10.1007/s11060-017-2469-x. Epub 2017 May 16.

PMID:
28510787
20.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

21.

Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.

Karmali R, Nabhan C, Petrich AM, Raizer J, Peace D, Lukas R, Gordon LI, Basu S, Chukkapalli V, Venugopal P.

Br J Haematol. 2017 Apr;177(1):72-79. doi: 10.1111/bjh.14522. Epub 2017 Feb 17.

PMID:
28211579
22.

Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.

Chamberlain MC, Colman H, Kim BT, Raizer J.

J Neurooncol. 2017 Feb;131(3):507-516. doi: 10.1007/s11060-016-2241-7. Epub 2017 Feb 16.

PMID:
28204914
23.

Leptomeningeal metastases: a RANO proposal for response criteria.

Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA.

Neuro Oncol. 2017 Apr 1;19(4):484-492. doi: 10.1093/neuonc/now183. Review.

24.

Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.

Phuphanich S, Raizer J, Chamberlain M, Canelos P, Narwal R, Hong S, Miday R, Nade M, Laubscher K.

J Neurooncol. 2017 Jan;131(1):185-191. doi: 10.1007/s11060-016-2287-6. Epub 2016 Nov 14.

PMID:
27844311
25.

Improving vaccine efficacy against malignant glioma.

Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, Binder DC, James CD, Wainwright DA.

Oncoimmunology. 2016 Jun 10;5(8):e1196311. doi: 10.1080/2162402X.2016.1196311. eCollection 2016 Aug. Review.

26.

A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.

Raizer JJ, Chandler JP, Ferrarese R, Grimm SA, Levy RM, Muro K, Rosenow J, Helenowski I, Rademaker A, Paton M, Bredel M.

J Neurooncol. 2016 Aug;129(1):139-46. doi: 10.1007/s11060-016-2156-3. Epub 2016 Jun 14.

PMID:
27300524
27.

RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma.

Das A, McDonald DG, Dixon-Mah YN, Jacqmin DJ, Samant VN, Vandergrift WA 3rd, Lindhorst SM, Cachia D, Varma AK, Vanek KN, Banik NL, Jenrette JM 3rd, Raizer JJ, Giglio P, Patel SJ.

Tumour Biol. 2016 Jun;37(6):7525-34. doi: 10.1007/s13277-015-4621-6. Epub 2015 Dec 18.

PMID:
26684801
28.

Bevacizumab for recurrent primary central nervous system lymphoma: a new treatment?

Nieto K, Gordon LI, Raizer J.

Neuro Oncol. 2015 Dec;17(12):1648-9. doi: 10.1093/neuonc/nov246. No abstract available.

29.

Central Nervous System Cancers, Version 1.2015.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM.

J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202.

PMID:
26483059
30.

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR; Brain Tumor Trials Collaborative.

J Neurooncol. 2016 Jan;126(1):185-192. doi: 10.1007/s11060-015-1958-z.

31.

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient.

Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL.

J Immunother Cancer. 2015 Sep 15;3:41. doi: 10.1186/s40425-015-0084-y. eCollection 2015.

32.

The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.

Zhai L, Dey M, Lauing KL, Gritsina G, Kaur R, Lukas RV, Nicholas MK, Rademaker AW, Dostal CR, McCusker RH, Raizer JJ, Parsa AT, Bloch O, Wainwright DA.

J Clin Neurosci. 2015 Dec;22(12):1964-8. doi: 10.1016/j.jocn.2015.06.018. Epub 2015 Aug 14.

33.

Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors.

Raizer JJ, Dixit KS.

Curr Treat Options Oncol. 2015 Aug;16(8):38. doi: 10.1007/s11864-015-0357-1. Review.

PMID:
26143268
34.

Financial burden experienced by patients undergoing treatment for malignant gliomas.

Kumthekar P, Stell BV, Jacobs DI, Helenowski IB, Rademaker AW, Grimm SA, Bennett CL, Raizer JJ.

Neurooncol Pract. 2014 Jun;1(2):71-76. Epub 2014 May 5.

35.

Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden.

Jacobs DI, Kumthekar P, Stell BV, Grimm SA, Rademaker AW, Rice L, Chandler JP, Muro K, Marymont M, Helenowski IB, Wagner LI, Raizer JJ.

Neurooncol Pract. 2014 Jun;1(2):47-54. Epub 2014 May 5.

36.

Geographic distribution of phlebotomine sandfly species (Diptera: Psychodidae) in Central-West Brazil.

Almeida PS, Andrade AJ, Sciamarelli A, Raizer J, Menegatti JA, Hermes SC, Carvalho Mdo S, Gurgel-Gonçalves R.

Mem Inst Oswaldo Cruz. 2015 Jun;110(4):551-9. doi: 10.1590/0074-02760140462. Epub 2015 May 26.

37.

Atypical meningioma: randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy.

Yoon H, Mehta MP, Perumal K, Helenowski IB, Chappell RJ, Akture E, Lin Y, Marymont MA, Sejpal S, Parsa A, Chandler JR, Bendok BR, Rosenow J, Salamat S, Kumthekar P, Raizer JK, Baskaya MK.

J Cancer Res Ther. 2015 Jan-Mar;11(1):59-66. doi: 10.4103/0973-1482.148708.

38.

A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/β-catenin signaling pathway.

Das A, Miller R, Lee P, Holden CA, Lindhorst SM, Jaboin J, Vandergrift WA 3rd, Banik NL, Giglio P, Varma AK, Raizer JJ, Patel SJ.

Tumour Biol. 2015 Sep;36(9):7027-34. doi: 10.1007/s13277-015-3388-0. Epub 2015 Apr 12.

PMID:
25864108
39.

Bevacizumab in high-grade gliomas: past, present, and future.

Curry RC, Dahiya S, Alva Venur V, Raizer JJ, Ahluwalia MS.

Expert Rev Anticancer Ther. 2015 Apr;15(4):387-97. doi: 10.1586/14737140.2015.1028376. Review.

PMID:
25797685
40.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY.

Neuro Oncol. 2015 Jun;17(6):862-7. doi: 10.1093/neuonc/nou350. Epub 2015 Jan 7. Erratum in: Neuro Oncol. 2015 Dec;17(12):1650.

41.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY.

Neurology. 2015 Jan 20;84(3):280-6. doi: 10.1212/WNL.0000000000001153. Epub 2014 Dec 19.

42.

Chemotherapy for low-grade gliomas: lessons and questions.

Raizer J.

Oncology (Williston Park). 2014 Dec;28(12):1043-4, 1051. No abstract available.

43.

Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.

Feng H, Li Y, Yin Y, Zhang W, Hou Y, Zhang L, Li Z, Xie B, Gao WQ, Sarkaria JN, Raizer JJ, James CD, Parsa AT, Hu B, Cheng SY.

Neuro Oncol. 2015 Jun;17(6):832-42. doi: 10.1093/neuonc/nou323. Epub 2014 Dec 2.

44.

Low-grade glioma.

Kumthekar P, Raizer J, Singh S.

Cancer Treat Res. 2015;163:75-87. doi: 10.1007/978-3-319-12048-5_5. Review.

PMID:
25468226
45.

Economics of Malignant Gliomas: A Critical Review.

Raizer JJ, Fitzner KA, Jacobs DI, Bennett CL, Liebling DB, Luu TH, Trifilio SM, Grimm SA, Fisher MJ, Haleem MS, Ray PS, McKoy JM, DeBoer R, Tulas KM, Deeb M, McKoy JM.

J Oncol Pract. 2015 Jan;11(1):e59-65. doi: 10.1200/JOP.2012.000560. Epub 2014 Dec 2.

46.

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M.

J Natl Compr Canc Netw. 2014 Nov;12(11):1517-23.

47.

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA.

J Neurosurg. 2015 Jan;122(1):4-23. doi: 10.3171/2014.7.JNS131644. Review.

48.

NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.

Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD.

Mol Cancer Ther. 2014 Dec;13(12):2919-29. doi: 10.1158/1535-7163.MCT-14-0306. Epub 2014 Oct 13.

49.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY.

J Clin Invest. 2014 Sep;124(9):3741-56. doi: 10.1172/JCI73093. Epub 2014 Jul 25.

50.

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.

Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA.

Neuro Oncol. 2014 Sep;16(9):1176-85. doi: 10.1093/neuonc/nou089. Epub 2014 May 27. Review.

Supplemental Content

Loading ...
Support Center